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A B S T R A C T   
Validation and characterisation of in vitro and pre-clinical animal models to support bio-enabling formulation 
development is of paramount importance. In this work, post-mortem gastric and small intestinal fluids were 
collected in the fasted, fed state and at five sample-points post administration of a placebo Self-Emulsifying Drug 
Delivery System (SEDDS) in the fasted state to pigs. Cryo-TEM and Negative Stain-TEM were used for ultra-
structure characterisation. Ex vivo solubility of fenofibrate was determined in the fasted-state, fed-state and post- 
SEDDS administration. Highest observed ex vivo drug solubility in intestinal fluids after SEDDS administration 
was used for optimising the biorelevant in vitro conditions to determine maximum solubility. Under microscopic 
evaluation, fasted, fed and SEDDS fluids resulted in different colloidal structures. Drug solubility appeared 
highest 1 hour post SEDDS administration, corresponding with presence of SEDDS lipid droplets. A 1:200 
dispersion of SEDDS in biorelevant media matched the highest observed ex vivo solubility upon SEDDS admin-
istration. Overall, impacts of this study include increasing evidence for the pig preclinical model to mimic drug 
solubility in humans, observations that SEDDS administration may poorly mimic colloidal structures observed 
under fed state, while microscopic and solubility porcine assessments provided a framework for increasingly bio- 
predictive in vitro tools.   
1. Introduction 
Trends in physicochemical properties of molecules in drug devel-
opment pipelines continuously display an increasing prevalence of 
poorly water soluble drugs (PWSD) (1, 2). Resultantly, the pharmaceu-
tical industry must adapt to ensure developability of such candidates. 
Solubility in the gastrointestinal tract (GIT) is an important parameter in 
guiding the oral developability classification, as previous estimates 
suggest approximately 40% of new chemical entities are rejected in 
early development owing to insufficient solubility (3). Prevalence of 
such challenging properties provokes a multifaceted response; including 
development of bio-enabling formulations, in addition to both devel-
opment and validation of in vitro tools and pre-clinical animal models to 
accurately forecast in vivo behaviour, together counteracting increasing 
product attrition. 
One common bio-enabling formulation strategy involves the use of 
self-emulsifying drug delivery systems (SEDDS) (4). SEDDS are a type of 
lipid-based formulation (LBF) composed of an isotropic mixture of oils, 
surfactants and co-solvents, designed to self-emulsify following disper-
sion within the GIT. SEDDS include various mixtures of lipophilic and/or 
hydrophilic surfactants, helping to emulate positive food effects expe-
rienced by many PWSD, as concentrations of bile salts and phospholipids 
Abbreviations: PWSD, Poorly Water-Soluble Drug; LBF, Lipid-Based Formulations; SEDDS, Self-emulsifying drug delivery systems; GIT, Gastrointestinal tract; DCS, 
Developability Classification System; BCS, Biopharmaceutics Classification System; TEM, Transmission Electron Microscopy; USI, Upper Small Intestine (Duodenum); 
MSI, Middle Small Intestine (Jejunum); LSI, Lower Small Intestine (Ileum); FaSSIF, Fasted State Simulated Intestinal Fluid; FaSSGF, Fasted State Simulated Gastric 
Fluids; FaSSIFp, Fasted State Simulated Intestinal Fluid of Pigs; FaHIF, Fasted State Human Intestinal Fluid; FeHIF, Fed State Human Intestinal Fluids; OrBiTo, Oral 
Biopharmaceutics Tools; SGFsp, Simulated Gastric Fluid without Pepsin. 
* Corresponding author. 
E-mail address: brendan.griffin@ucc.ie (B.T. Griffin).  
Contents lists available at ScienceDirect 
European Journal of Pharmaceutical Sciences 
journal homepage: www.elsevier.com/locate/ejps 
https://doi.org/10.1016/j.ejps.2021.105778 
Received 28 January 2021; Received in revised form 22 February 2021; Accepted 23 February 2021   
European Journal of Pharmaceutical Sciences 161 (2021) 105778
2
are increased in the fed state (5). These endogenous surfactants, in 
combination with lipid digestion products, may increase the solubili-
sation capacity in the GIT fluids for PWSD through creation of a range of 
colloidal structures. In this heterogeneous environment, the solubility 
deficit between the fasted and fed state can be bridged (6, 7). 
Successful application of such bio-enabling oral drug delivery sys-
tems is often dependent on existence of efficacious screening processes 
and predictive in vitro models simulating the GIT. These investigations 
provide vital tools for progression of bio-enabling drug delivery systems, 
ideally simulating the likely in vivo human response in an efficient and 
cost-effective manner. However, lack of accurate in vitro predictions can 
result in a reluctance by the pharmaceutical industry to utilise such non- 
traditional formulation approaches. The past two decades have wit-
nessed a surge in development of in vitro models for SEDDS including 
biorelevant dispersion, digestion and permeability testing, where 
increasingly detailed simulations of the GIT are seen (8-11). Addition-
ally, prevalence of computational modelling, as well as in silico simu-
lations based on physiology-based pharmacokinetic (PBPK) modelling 
platforms, such as Gastroplus, Simcyp and PK-Sim are steadily 
increasing (12, 13). While collaborative efforts are being made to 
improve in vitro and in silico tools (14, 15), the complexity of endogenous 
formulation processing results in gaps in development of accurate in vivo 
predictions. Resultantly, one method to increase prediction accuracy 
involves validation and optimisation of in vitro simulation conditions, 
via introduction of increasingly physiologically and bio-
pharmaceutically relevant input parameters. 
In addition, pre-clinical animal models provide invaluable early 
performance indicators for oral bioavailability, formulation perfor-
mance and impact of dosing conditions (e.g. food effects) (13, 16-18). 
Usually this involves collection of plasma samples, but an additional 
opportunity exists for collation of animal gastrointestinal (GI) luminal 
aspirates and fluids for solubility screening (19).The utility of the pig 
model to reliably predict human in vivo behaviour has been previously 
reviewed (17), demonstrating high similarity with human GI conditions 
and physiology of commonly used breeds such as the domestic 
miniature-sized pig. However, while similar in anatomy and physiology, 
the chief principle of utilising animal models is their ability to provide a 
reliable estimate of in vivo performance of drug delivery systems in 
humans. It is, therefore, crucial that all biopharmaceutical processes are 
adequately simulated, including the ability of the intestinal fluids in the 
target species to provide a comparable solubilisation capacity to their 
human equivalents (3, 20). Resultantly, previous quantitative assess-
ment of the composition of porcine GI fluids revealed differences in both 
the concentrations of solubilising components and in the relative 
quantities of the major bile acids when compared to human intestinal 
fluids (21). These observations led to the development of a porcine 
biorelevant medium, Fasted State Simulated Intestinal Fluid of pigs 
(FaSSIFp) based on the composition of porcine GI fluids with respect to 
pH, buffer capacity, osmolality, surface tension, as well as the bile salt, 
phospholipid and free fatty acid content in fasted state pigs (21). As 
these endogenous compounds and their interactions with LBF excipients 
have been suggested to be vital for solubilisation of PWSD in the GIT 
(19), further characterisation evaluating similarities and differences in 
the fluid ultrastructure’s formed in both human and porcine fluids 
through microscopic evaluation is warranted. Furthermore, additional 
characterisation of fluid structures observed following SEDDS adminis-
tration may provide insights regarding the capability of SEDDS to mimic 
post-prandial enhanced solubilisation and improve understanding of the 
mechanisms by which this enhanced solubilisation is generated. 
In response to the necessity for validated in vitro models, this 
research sought to assess if a qualitative evaluation of porcine fluid ul-
trastructure, as discussed above, in combination with quantitative as-
sessments of drug solubility in these fluids, could inform increasingly 
bio-predictive in vitro tools. In order to achieve this aim, morpholog-
ical characteristics of porcine luminal media in the fasted and fed state, 
as well as at five time points post SEDDS ingestion were conducted at the 
ultrastructure level. While similar microscopic analysis of both human 
and simulated fluids have been conducted (5, 22), this research provides 
the first comparative analysis of porcine fluids using two complemen-
tary techniques of Cryogenic Transmission Electron Microscopy (Cry-
o-TEM) and Negative Stain TEM, previously demonstrated as excellent 
tools for such analyses (23). These qualitative observations were then 
compared to ex vivo solubility values to investigate any time dependent 
change in drug solubility post SEDDS ingestion. Fenofibrate was chosen 
as a BCS Class II neutral drug, and has previously displayed food effects 
in landrace pigs (18), where the lack of a pH effect between gastric and 
intestinal samples allowed direct comparisons. Using combined knowl-
edge from the microscopic images and quantitative solubility studies, it 
was analysed if the maximum observed ex vivo solubility with SEDDS 
could be used to inform more physiologically relevant input parameters, 
supporting refinement of in vitro models for SEDDS. 
2. Materials and methods 
2.1. Materials 
Fenofibrate was purchased from Kemprotec Ltd. (UK). Hard gelatine 
capsules (00EL Licaps®) were obtained from Capsugel®. All food com-
ponents used in preparing the FDA recommended breakfast were pur-
chased commercially. Fasted State Simulated Intestinal Fluid (FaSSIF) 
and Fasted State Simulated Gastric Fluids (FaSSGF) were produced from 
FaSSIF/FeSSIF/FaSSGF powder obtained from Biorelevant.com (Croy-
den, UK). For the fasted state simulated porcine media (FaSSIFp); Lipoid 
E PC S was obtained from Lipoid GmbH (Germany), Sodium taur-
odeoxycholate; Sodium hydroxide (NaOH) pellets; Chloroform; Sodium 
chloride (NaCl); Sodium dihydrogen phosphate monohydrate; Sodium 
oleate were purchased from Sigma Aldrich (Ireland) and sodium taur-
ocholate was ordered from Thermo Scientific Ltd., Alfa Aesar (UK). 
Olive Oil, Tween 85 and Kolliphor RH 40 were all purchased from 
Sigma-Aldrich (Ireland). All other chemicals and solvents were of 
analytical grade or HPLC grade, respectively, and were purchased from 
Sigma–Aldrich (Ireland) and used as received. Water of HPLC grade was 
produced using a MilliQ system (Merck KGaA, Germany). 
2.2. Gastric and intestinal fluid collection 
This study was carried out under a licence issued by the Health 
Products Regulatory Authority (HPRA), Ireland and EU Statutory In-
struments. Local University Ethical Committee approval was obtained. 
11 male landrace pigs were sourced locally and housed individually at 
the Universities Biological Services Unit (17-20 kg and mean 18.3 kg). 
Pigs were fed approximately 175 g of standard weanling pig pellet feed 
twice daily and given free access to water. The final feed of 175 g was 
given 24 h prior to dosing. Pigs were grouped into either fasted state (3 
pigs), fed state (3 pigs) or SEDDS group (5 pigs) for the post mortem 
assessment. 
The following post mortem fluid collection protocol was repeated for 
the 3 groups. Firstly, the fasted state group (following a 24 hour fast) 
received 50 mL of water via a syringe 30 min prior to euthanasia and 
post-mortem sampling. The study was designed to mimic dosage condi-
tions under a fasted leg of a pre-clinical study, therefore 50 mL of water 
was provided to mimic administration of a dose with water in pigs and 
access to water was thereafter restricted until sampling, in accordance 
with the standard protocol applied by Henze et al. (18). The fed state 
group of 3 pigs, were fed a half portion of a standard high-caloric, 
high-fat FDA breakfast, the mass which equated to approximately 
18–20 g/kg of body weight. The fed group were given this FDA breakfast 
two hours prior to euthanasia and post-mortem luminal fluid sampling, 
where water was again restricted until sampling. The SEDDS group was 
orally administered with 1 g of a Type IIIa SEDDS via a dosing device in a 
gelatine capsule (00EL Licaps®, Capsugel®) followed by 50 mL of water 
via syringe. 1 g SEDDS was chosen to be representative of a commonly 
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administered amount in comparative animal studies using the landrace 
pig. SEDDS consisted of 40% Olive Oil (long chain triglyceride), 40% 
Tween 85 (co-surfactant) and 20% Kolliphor RH 40 (surfactant). Access 
to water was restricted up to 3 h post dosing. All pigs were euthanized 
humanely by intravenous injection of pentobarbital sodium followed by 
potassium chloride. The peritoneal cavity was exposed by midline 
incision and the stomach and small intestine were isolated. Occluding 
ligatures were applied proximal to the cardiac sphincter and distal to the 
pyloric sphincter as well as at the proximal and distal ends of the small 
intestine. Once both ends were secured, the stomach and small intestine 
were removed from the peritoneal cavity. The small intestine was sub-
divided into three sections approximating to the duodenum (USI), 
jejunum (MSI) and ileum (LSI). Gastric, USI, MSI and LSI luminal fluids 
were then collected and transferred to sterile 50 mL sample tubes at time 
intervals of 0.5, 1, 2, 3 and 4 h post dosing respectively (n = 1). Further 
digestion in the samples post-sampling was inhibited with 1 µM orlistat 
(24). All samples were first immediately frozen at -20◦C, then stored at 
-80◦C until further analysis. 
2.3. Cryogenic and negative stain transmission electron microscopy 
studies 
All GI samples (fasted, fed and SEDDS) were centrifuged at 30,000 ×
g for 15 min at room temperature in an Optima MAX-XP Ultracentrifuge 
from Beckman Coulter (Brea, CA, USA) and the supernatant collected for 
ultrastructure characterisation. Cryo-TEM samples were prepared by 
depositing 3 µL of the supernatant (some diluted in ultrapure water to 
ensure proper vitrification) on glow-discharged 300 mesh lacey carbon 
grids from Ted Pella Inc. (Redding, CA, USA). Sample vitrification was 
then carried out in liquid ethane using a Vitrobot Mark IV from FEI 
(Hillsboro, OR, USA) under controlled (4 ◦C, 100% relative humidity) 
and automated conditions (blot time 3 s, blot force ’0′). The vitrified 
samples were then kept in liquid nitrogen and images obtained with an 
accelerating voltage of 200 kV using a Tecnai G2 20 TWIN Transmission 
Electron Microscope equipped with a 4K CCD Eagle digital camera from 
FEI. Negative Stain TEM samples were prepared by depositing 4 µL on 
glow-discharged 200 mesh carbon grids from Ted Pella Inc. After 60 s, 
10μL of water was added and the grids carefully aspirated using the edge 
of a filter paper. Gastric samples were then stained with 10μL of a uranyl 
acetate solution (pH 2) for 30s, while intestinal samples were stained 
with a phosphotungstic acid solution (pH 7). Lastly, the grids were 
washed twice with 10μL water and aspirated. Images were recorded 
using a CM100 TWIN Transmission Electron Microscope (Philips, 
Amsterdam, The Netherlands) with an accelerating voltage of 100 kV 
and equipped with a side-mounted Veleta Camera (Olympus). Use of 
both techniques allowed for cross-referencing of samples to verify 
presence of different colloidal structures and increased the robustness of 
the analysis. 
2.4. Solubility studies 
Ex vivo apparent solubility studies of fenofibrate were conducted on 
gastric and USI samples obtained from the SEDDS group at 0.5, 1, 2, 3 
and 4 h post sampling, as well as fasted and fed gastric and USI samples. 
pH of the SEDDS samples was measured using a using a Model 3510 pH/ 
mV/Temperature Meter (Jenway, UK). Fenofibrate was added in excess 
to triplicate glass vials containing a specified volume of each fluid pre-
heated to 37◦C and a magnetic stirrer. Vials were placed on a stirring 
plate at 300 rpm (Mixdrive 15, 2MAG, Germany) in a 37◦C incubator for 
the period of the study. 150 µL samples were removed at 2, 4, 6 and 24 h, 
with the mean of the 24h samples used for data analysis. Samples were 
centrifuged at 11,400 × g for 10 min at 37◦C (Mikro 200 R, Andreas 
Hettich GmbH & Co. KG, Germany), followed by a 10-fold dilution in 
acetonitrile. Next the samples were centrifuged a second time to remove 
precipitated proteins (11,400 × g, 10 min, 4◦C). Supernatant was then 
transferred to a separate centrifuge tube and suitably diluted in mobile 
phase in preparation for analysis via RP-HPLC/UV. 
In vitro solubility studies were carried out using commercial FaSSGF, 
FaSSIF along with FaSSIFp previously described (21). FaSSGF and FaS-
SIF were prepared using the Biorelevant.com protocol (Croyden, UK) 
and FaSSIFp was prepared using the previously published protocol (21). 
Fenofibrate solubility was obtained in FaSSGF, FaSSIF and FaSSIFp, as 
well as 1:50, 1:100, 1:200, 1:500 and 1:1000 i.e. 1 g:50 mL, 1 g:100 mL, 
1 g:200 mL, 1 g:500 mL and 1 g:1000 mL, dilutions of SEDDS dispersed 
through mixing in the biorelevant medias (n = 3). The same method as 
above was followed, however, only one centrifugation at 37◦C, 11,400 
× g for 15 min was used. The solubility result for 1:200 dispersion of 
SEDDS in FaSSIF was obtained from a previous publication (25). 
2.5. RP-HPLC/UV analysis 
Detection of fenofibrate was conducted using an Agilent 1200 series 
HPLC system comprising a binary pump, degasser, autosampler and 
variable wavelength detector. Data analysis was conducted with 
EZChrom Elite version 3.2. A Waters Symmetry® C18 column (4.6 ×
150 mm, 5 µm) maintained at 25◦C was used during separation. The 
mobile phase used consisted of 80:20 (v/v) acetonitrile and sodium 
acetate 25 mM buffer adjusted to pH 5. The flow rate was 1 mL/min and 
the detection wavelength was 287 nm. The drug concentration in each 
vial was calculated from a calibration curve run on the same day. The 
solubility value presented was the mean value of the 24 h triplicate 
samples. The analysis displayed linearity over the range 0.01-25 µg/mL 
(r2 > 0.999). The precision of the method at 1 and 10 µg/mL, expressed 
as the coefficient of variation, was 0.442% and 0.327% within days and 
2.796% and 2.92% between days respectively. 
2.6. Statistical analysis 
Prior to statistical analysis, drug solubility data in the different ex 
vivo and in vitro media were compared to Levene’s Test for Equality of 
Variances where a p-value <0.05 indicated a violation of equal variance. 
Solubility comparisons were conducted using a one-way ANOVA with 
pairwise comparisons of the groups completed using Tukey’s multiple 
comparison test. All statistical analysis was conducted using SPSS (IBM, 
California) as p-value <0.05 indicated a significant result. Graphs of 
solubility and pH were obtained using Prism 5 (GraphPad Software, CA, 
USA). 
2.7. In silico prediction 
A multiple linear regression (MLR) equation previously developed to 
predict the solubility ratio (SR) of drugs upon SEDDS dispersion in 
FaSSIF relative to FaSSIF solubility (25) was employed. This equation 
was previously produced using Excel (Microsoft Office, 2016), where 
correlations were investigated between a selection of drug properties 
and SR for a database of 30 PWSD, resulting in Eq. 1: 
logSR = 0.54 + 0.17(logD6.5) + 1.04(F AromB) − 0.01(Tm) (1) 
Where logD6.5 is the partition coefficient at pH 6.5, F_AromB is ar-
omatic bonds as a fraction of total bonds and Tm is the melting point of 
the drug (Fenofibrate). The antilog of the result was then multiplied by 
the solubility of fenofibrate in FaSSIF obtained from literature (26), in 
order to obtain the prediction of fenofibrate solubility upon SEDDS 
dispersion in FaSSIF and compared to the ex vivo and in vitro results 
obtained in this study. 
3. Results 
3.1. pH characterisation of gastric and intestinal porcine media with a 
SEDDS 
In order to assess if administration of a SEDDS would alter the pH 
H. Bennett-Lenane et al.                                                                                                                                                                                                                       
European Journal of Pharmaceutical Sciences 161 (2021) 105778
4
profile in the GI fluids of pigs, post mortem samples of both the gastric 
and USI samples were collected at various time points post SEDDS 
administration in the fasted state. In total five pigs were administered a 
SEDDS formulation, and post mortem samples of the gastric and USI 
samples were collected at 0.5,1,2,3 and 4 hours (n = 1) (Fig. 1). Due to 
the limited sample availability, no pH could be obtained for USI at 0.5 h. 
In terms of the gastric samples, after 30 min the low pH value observed 
was in line with previously reported values of fasted state pH in landrace 
pigs (range reported 1.2 - 4.0) (17). However, at 1 h the pH observed was 
higher (5.37), while values appeared to subsequently fall back to low 
levels thereafter. However, given that only one sample was available, 
limited statistical relevance can be derived. The pH of the USI samples 
ranged from 5.06 - 7.67, consistent with previous fasted-state observa-
tions in the landrace pig (17). Overall, it would appear that adminis-
tration of SEDDS has a limited effect overall on gastric and USI pH over 
the 4 hour period, and while further studies would be required in a 
larger number pigs, to assess a transient increase in gastric pH, such 
studies were not considered justified given the findings of this initial 
pilot study. 
3.2. Microscopic evaluation of fasted and fed state gastric and intestinal 
porcine fluids 
Two complementary techniques of Cryo-TEM and Negative Stain 
TEM were used (Fig. 2). For the fasted-state, Cryo-TEM and Negative 
Stain gastric images revealed the presence of small structures, which 
may represent micelles and a vesicle/lipid droplet (~100-150 nm). In 
the USI fasted state samples, bilamellar vesicles (200 nm), a ruptured 
vesicle (~400 nm) and small micelle-like structures (10-30 nm) were the 
predominant features. A MSI fasted sample also revealed an abundance 
of fiber-like structures. In the fed-state gastric images, while micelles 
(10-50 nm) were seen, overall these images displayed evidence of a 
heterogeneous population with clustering of structures and higher 
concentrations of colloidal structures of different sizes ranging from 
approximately 50-500 nm. Structures observed included unilamellar 
vesicles, multi-compartmental vesicles and multilamellar vesicles and 
lipid droplets. In terms of the USI images, once again clusters of multi-
vesicular structures including unilamellar, bilamellar and multi- 
compartmental vesicles were dominant (approximately 100-600 nm). 
Furthermore, either a mixed micelle or lipid droplet was seen (100 nm), 
as well as a mixture of micelles and vesicles in the Negative Stain TEM 
USI and MSI samples. 
3.3. Microscopic evaluation of porcine gastric and intestinal fluids post 
administration of a placebo SEDDS 
Changes in luminal fluid ultrastructure were observed at different 
time points (0.5, 1, 2, 3, 4 h) post SEDDS oral administration in the 
fasted state. Cryo-TEM images were obtained for the 0.5, 1 and 2 h 
SEDDS samples only (due to sample unsuitability) and Negative Stain 
TEM images for each sampling point, except 0.5 h USI and MSI and 3 h 
MSI (no sample collection) (Figs. 3 and 4). When compared to the fasted 
state gastric composition, high concentrations of small micelles 10-40 
nm are seen in the 0.5, 1 and 2 h Cryo-TEM images, in addition to 
small lipid structures (20-60 nm) after SEDDS administration. In terms 
of the USI Cryo-TEM images, the 1 h samples demonstrated examples of 
what resembled lipid droplet clusters, similar in appearance to struc-
tures seen in the 2 h gastric and fed state USI samples (Fig. 3). SEDDS 
administration did not appear to produce similar multivesicular struc-
tures to the fed state, while a clear difference in composition was 
observed from the fasted state in terms of higher concentrations of mi-
celles and clusters of lipids droplets, particularly at the 1 h sampling 
point. 
Similarly, Negative Stain TEM revealed differences between SEDDS 
administration and the fasted and fed state (Fig. 4). Firstly, similar to 
Cryo-TEM a high concentration of small lipid structures 10-40 nm were 
visualised in the 0.5 h gastric image. The 1 h gastric image revealed a 
heterogeneous mix of structures with a higher concentration of struc-
tures versus the fasted state. A large lipid droplet or vesicle, approxi-
mately 200-250 nm in diameter, could be observed and was similar in 
appearance to structures observed in the fed state gastric sample. In the 
2 h gastric, USI and MSI samples, vesicles/lipid droplets (100-200 nm) 
were observed, while the compositional characteristics of the 3 h sam-
ples depicted a great mix of micelles and vesicles of 10-200 nm. Inter-
estingly, the 4 h samples, appeared similar in overall composition to the 
previous fasted state images, in terms of appearance of small structures 
resembling micelles (10-50 nm), and fiber-like structures. 
3.4. Fenofibrate solubility in pig gastric and intestinal media post ingestion 
of a placebo SEDDS 
To investigate potential correlations with the colloidal species 
visualised upon microscopic evaluation of the SEDDS samples, ex vivo 
solubility studies using gastric and USI fluids were conducted. These 
results were also compared to the ex vivo fed, fasted and biorelevant 
media solubility results (Fig. 5). As seen in Fig. 5, in both the gastric and 
USI samples, the highest ex vivo solubility was observed 1 h post SEDDS 
ingestion where both samples displayed similar values, while the lowest 
solubility was at 4 h. In terms of gastric solubility at each time point, 
fenofibrate solubility increased from 0.5 h (189 ± 10 µg/mL) to 1 h (285 
± 31 µg/mL) post ingestion (Fig. 5). After the 1 h sample, a decrease in 
drug solubility was seen, where 2 h (61 ± 8 µg/mL) and 3 h (68 ± 4 µg/ 
mL) samples displayed similar solubility, both below the value obtained 
from the gastric fed state sample (86 ± 6 µg/mL). Finally, the 4 h sample 
displayed a low drug solubility (9 ± 4 µg/mL), similar to the value ob-
tained from fasted gastric media (6 ± 2 µg/mL). USI samples displayed a 
similar solubility trend, though no sample fluid could be collected for 
the 0.5 h sample thus, was not available for comparisons. Once again, 
the 1 h time point demonstrated the highest drug solubility (271 ± 36 
µg/mL). After this time, drug solubility decreased substantially as sol-
ubility at 2 h (117 ± 12 µg/mL) was higher than the 3 h (85 ± 9 µg/mL) 
sample in contrast to the gastric samples where 2 h and 3 h displayed 
similar values. In this case, the 2 h sample did exceed the fed state USI 
solubility obtained (104 ± 19 µg/mL), however not significantly (p >
0.05). Again, the lowest drug solubility was observed at 4 h (4 ± 1 µg/ 
mL), also similar to the fasted state USI sample (7 ± 1 µg/mL). 
Fig. 1. pH values obtained as a function of time from gastric (black circles) and 
USI samples (black squares) following administration of a placebo SEDDS to 
fasted pigs (n=1). 
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3.5. Exploration of in vitro SEDDS screening tool using enhanced 
biorelevant media and investigation of appropriate dilution conditions 
Apparent solubility was determined in SEDDS dispersions in simu-
lated human or simulated porcine fluids and compared to the apparent 
solubility from the ex vivo studies where 1 g of SEDDS was administered. 
The gastric and intestinal ex vivo 1 h samples were taken as an 
approximation of the maximum in vivo solubility with SEDDS, and 
consequently, as the value which the in vitro conditions should replicate. 
Apparent solubility was determined in 1:50, 1:100, 1:200, 1:500 or 
1:1000 dispersions of SEDDS in the various biorelevant medias (FaSSGF, 
FaSSIF, FaSSIFp). All medias containing dispersed SEDDS were signifi-
cantly different from the solubility of fenofibrate in the respective me-
dias alone ie. FaSSGF (0.25 ± 0.01 µg/mL), FaSSIF (9.6 ± 1.4 µg/mL) 
and FaSSIFp (15.69 ± 0.9 µg/mL). One-way ANOVA analysis and a 
Tukey post-test found that in the three medias, no significant difference 
was found between the ex vivo results and in vitro solubility in the 1:200 
SEDDS media (Fig. 6). Conversely, in all three media, the 1:50, 1:100, 
1:500 and 1:1000 dispersions significantly differed (p < 0.05) from the 
ex vivo 1 h gastric and 1 h USI results respectively. The 1 h USI ex vivo 
Fig. 2. Cryo-TEM and Negative Stain TEM images of fasted and fed state (2 h post-prandial) Gastric and Intestinal samples. Letters indicate representative colloidal 
structures. A (Multi-Compartmental Vesicles 200-800 nm), B (Lipid droplet), C (Unilamellar and Bilamellar Vesicles or Lipid Droplets 150-400 nm), D (Ruptured 
Vesicle 400 nm), E (Fiber-like structures), F (Micelles/Small structures 10-50 nm). Measurement scales are shown. To ensure proper vitrification the fed state USI 
samples were diluted in ultrapure water. 
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solubility and 1:200 in vitro solubility results in FaSSIF were also not 
significantly different from the solubility predicted from a previously 
published equation which predicts drug solubility gain upon SEDDS 
dispersion (25). 
4. Discussion 
The increasing demand for bio-enabling drug delivery systems has 
generated a complementary necessity for predictive tools to support 
data-driven, model-informed formulation development. Ability to 
confidently discriminate formulation performance using in vitro tools is 
key for successful implementation of modern enabling drug delivery 
approaches. While combined pressures of traditional production famil-
iarity, cost effectiveness and time constraints reinforce the importance 
of both accurate and efficient tools to encourage adoption of novel bio- 
enabling technologies. In recent decades, research has focused on 
standardization and increasing the physiological relevance of such tools 
(27). However, significant gaps in understanding limit ability to 
consistently predict in vivo drug luminal behaviour. Accordingly, the 
OrBiTo (Oral Biopharmaceutics Tools) project collaborators have high-
lighted importance of validation of in vitro and in silico models, through 
identifying key in vivo processes to be simulated and optimizing exper-
imental inputs to reflect the identified variables (14, 27). Consequently, 
this research aimed to establish if, through microscopic and quantitative 
assessment of porcine fluids, in vitro simulation conditions could be 
improved through increasingly physiologically relevant input parame-
ters. It is hoped that such a refinement of in vitro conditions can support 
the developability of drugs with SEDDS, through the facilitation of 
increasingly accurate in vitro dose number predictions. 
The first step in achieving this aim involved obtaining an improved 
understanding of the landrace pig model, via a microscopic characteri-
sation of pig luminal fluid ultrastructure. Aiming to reinforce the utility 
of the landrace pig model, while also aiding creation of increasingly bio- 
reflective in vitro conditions. Morphological characterisations on gastric, 
USI and MSI fluids were conducted using two microscopic techniques; 
Cryo-TEM and Negative Stain TEM. Firstly, fasted and fed state ultra-
structures were microscopically compared and contrasted. Distinct 
morphological differences were observed between the fasted and fed 
state samples due to increased prevalence of clustering and generally 
larger structures in the latter. The exact composition of the fasted gastric 
samples were more difficult to elucidate due to the lack of comparative 
studies investigating human gastric fluids, perhaps suggesting scope for 
future research. For example, the somewhat unexpected presence of 
small micelle resembling structures in both the fasted and 4 h SEDDS 
gastric samples, is in line previous reports of high bile salt concentra-
tions in the landrace pig stomach compared to humans (21). Most likely 
reflecting reflux of bile from the pig duodenum to the stomach. In terms 
of intestinal samples, the fasted intestinal fluids did suggest, in addition 
to fiber-like structures and vesicles, evidence of spherical micelles, 
previously shown to be abundant in FaSSIF and Fasted State Human 
Intestinal Fluids (FaHIF) (5, 22, 23). Similar vesicular components of 
approximately 100 nm have also been found in FaSSIF (5, 28). 
In contrast, the more complex composition of the fed state samples 
displayed evidence of clustering and larger multivesicular structures. 
The heterogeneous fed state presentation was expected as previous 
research demonstrated large variability in fed state human intestinal 
fluids (FeHIF) compared to FaHIF ultrastructure (23). The irregular 
appearance of some larger structures (>200 nm) has previously been 
Fig. 3. Cryo-TEM images of SEDDS Gastric and USI fluids at 0.5, 1 and 2 h post SEDDS administration. Letters indicate representative colloidal structures. A 
(Unilamellar Vesicles 100-600 nm), B (Lipid Droplet), C (Small Lipid Structures 20-60 nm), D (Small Micelles 10-40 nm). A 200 nm scale is shown for all images. To 
aid proper vitrification the 1h USI samples were diluted in ultrapure water. 
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related to their dynamic transient nature as intermediate phases (29, 
30). The fed state images in this study resembled the ultrastructure of 
FeSSIF including micelles and structures ranging from unilamellar to 
multicompartmental vesicles (23). This is reflective of previous obser-
vations that while uni-, bi- and multilamellar vesicles dominate in FeHIF 
they are rarely seen in FaHIF (22). However, upon comparison of the 
porcine fed state intestinal fluid to fed state human intestinal fluids, the 
structures observed appeared generally smaller in these porcine sam-
ples, as numerous elongated structures from 1-10 µm have been 
observed in FeHIF (23, 29, 31). While similar structures would be ex-
pected in general, significant differences in ultrastructure between pigs 
and humans is likely related to differences in rates of digestion, major 
primary bile acids (17), total phospholipid and cholesterol concentra-
tions along with differences in bile salt: phospholipid ratios (21). When 
compared to previous work demonstrating capacity for landrace pigs to 
predict food effects (18), from these images, it is clear that such an effect 
is produced through large clusters of heterogeneous vesicular structures 
in the fed state compared to the fasted state, capable of increasing the 
solubility of PWSD. Accordingly, an impact of this work is that porcine 
GI fluid ultrastructure, while demonstrating differences to human and 
simulated fluids, also shares common characteristics of these fluids, 
aiding its simulation of human luminal fluids. 
Microscopic analysis was additionally conducted to investigate how 
porcine luminal fluids responded to SEDDS administration. Similar to 
the food effect, understanding of the in vivo SEDDS solubilisation process 
is a key consideration for the development of predictive tools. SEDDS 
performance is often related to a bridging of the fasted-fed solubility 
gap, therefore, it was investigated if SEDDS administration led to pro-
duction of colloidal species more closely resembling the fed state. Im-
ages of gastric and intestinal media samples taken periodically up to four 
hours post placebo SEDDS administration revealed time dependent 
SEDDS processing in vivo through differences in colloidal and lipid 
structures. Compared to fasted gastric samples, high concentrations of 
small micelles ranging from 20-40 nm and larger lipid structures were 
seen in the 0.5 h gastric SEDDS sample, resembling higher concentra-
tions of small micelles previously seen in fed state simulated intestinal 
fluids (FeSSIF) and FeHIF (5, 23). The 1 h SEDDS USI samples displayed 
a large unilamellar vesicle and clusters of lipid droplets, similar to the 
USI fed sample, previously observed in FeSSIF, FeSSIF-V2 and FeHIF 
(23, 31). While a similar lipid droplet was seen in the 2 h gastric sample. 
From these images it appears that the SEDDS droplets formed ranged 
from 100-200 nm approximately. This can be compared to smaller 
previous size estimates of 44.76 ± 0.303 nm and 51.7 ± 0.8 nm observed 
for this SEDDS dispersed in FaSSIF and simulated gastric fluid without 
pepsin (SGFsp) respectively (25, 32). However, effect of digestion on 
droplet size was not accounted for in these previous studies. This along 
Fig. 4. Negative Stain TEM images of SEDDS gastric and intestinal fluids at 0.5, 1, 2, 3 and 4 h post placebo SEDDS administration. Letters indicate representative 
colloidal structures. A (Vesicles 200-400 nm), B (Fiber-like Structures), C (Micelles/Small Structures 10-60 nm), D (Small Lipid Structures 10-40 nm). Measurement 
scales are shown for each image. 
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with differences in bile salt and phospholipid constituents and concen-
trations between the in vivo porcine and human simulated media, likely 
explains the smaller sizes seen. 
From these images it appears that SEDDS administration does not 
result in colloidal structures of the same complexity and size of fed state 
fluids, with the differences in types and concentrations of lipids present, 
along with the added complexity of the surfactant present in the SEDDS 
samples playing a role. In contrast, clusters of lipid droplets from SEDDS 
processing were seen, predominantly in numerous 1 h USI samples. This 
can be compared to previous work where small micelles and clusters of 
lipid droplets were microscopically observed at the beginning of lipol-
ysis during in vitro SEDDS digestion and fewer lipid droplets were seen as 
time progressed, suggesting complete digestion (33). Clear differences 
between the 0.5 h to 4 h SEDDS samples were seen. When compared to 
the fasted state Negative Stain TEM images, similarities were perceived 
with the 4 h SEDDS images in terms of the predominant presence of 
fiber-like structures and small structures resembling micelles. Overall, 
this microscopic assessment suggests that the colloidal structures formed 
post SEDDS ingestion, while demonstrating increased colloid numbers 
relative to the fasted state, appear less complex than fed state fluids. 
While other physiological effects such as transit times may also play a 
role in differences seen in the media. 
Following the observation of varied colloidal structures in the gastric 
and intestinal fluids, and presence of lipid droplet clusters in the 1 h USI 
sample during microscopic analysis, it was then assessed if these qual-
itative observations could be correlated to time dependent changes in 
fenofibrate solubility from 0.5 h up to 4 h post SEDDS administration. 
Accordingly, the differing drug solubility’s seen at the various time 
points can be related to time dependant digestion of the vehicle and 
potential on-going lipid absorption. Solubility in both the gastric and 
USI samples was highest at 1 h post administration, exceeding fed state 
solubility, before decreasing at 4 h to levels similar to fasted state gastric 
and USI fluid and simulated fasted media. Resultantly, for fenofibrate, 
which displays a high solubility in this SEDDS (96.6 ± 3.4 mg/mL) (32). 
It appears to be the presence of the SEDDS lipid droplets, as seen in the 1 
h USI images, which are likely to be the key reservoirs of drug, main-
taining high solubilisation capacity. 
In summation, the images 1 h after SEDDS administration, the time 
of maximum observed ex vivo drug solubility, appeared different in 
colloidal ultrastructure composition, compared to the fasted state fluid, 
and also the fed state fluids 2 h after feeding. In the fed state, the lipid 
load produced is likely higher and more diverse, reflecting the 
complexity of the meal composition, likely contributing to differences 
observed with the SEDDS samples. While it appears from this study that 
the increased fenofibrate solubilisation using SEDDS is primarily driven 
through presence of SEDDS lipid droplets. It must be acknowledged that 
a different SEDDS may produce a different outcome in such a study and 
these results represent a snapshot reflecting the ingested type and 
amount of SEDDS ingested. Any solubilising effect of the SEDDS was lost 
at 4 h, where fenofibrate solubility mirrored fasted state gastric and USI 
values. In agreement, the Cryo-TEM 4 h images resembled the fasted 
state, with these results both suggesting that by this time the GIT had 
sufficiently processed the SEDDS, and digestion and absorption was 
complete. A contributing factor may also be that from 3 h after SEDDS 
administration pigs received ad libitum water access, potentially accel-
erating flushing of the SEDDS at 4 h. 
Previous research has investigated the drug solubilisation effect of 
carvedilol in canine intestinal fluids, where administration of 2 g of LBF 
resulted in a significantly higher solubility in fluids collected 5-20 min 
after administration versus 1 g of LBF or water (34). This higher 
Fig. 5. A) Fenofibrate solubility in gastric porcine luminal fluids 0.5, 1, 2, 3 and 4 h post placebo SEDDS ingestion for five pigs (Gastric SEDDS Ex Vivo) compared to 
fasted and fed gastric porcine (2 h post-prandial) and FaSSGF apparent solubility (n = 3). B) Fenofibrate solubility in USI porcine luminal fluids 1, 2, 3 and 4 h post 
placebo SEDDS ingestion for four pigs (USI SEDDS Ex Vivo) compared to fasted and fed USI, FaSSIF, FeSSIF and FaSSIFp solubility (n = 3). 
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solubility was only seen for the 5-20 min samples, and not samples taken 
at 0-5 min or 20-90 min after LBF administration. Differences in the 
timeframe of maximum observed solubility between these two studies is 
likely as a result of the previously discussed differences in absorption 
rates between canines versus pigs. Where the rate of drug absorption and 
gastric emptying in pigs is suggested to be marginally slower than ca-
nines (17). Meanwhile, in this study, solubility in fasted and fed state ex 
vivo USI samples, 7 ± 1 and 104 ± 19 µg/mL, respectively, appeared 
similar to reported human values for fenofibrate solubility in FaHIF (20 
± 26 µg/mL) and FeHIF (148 ± 60 µg/mL) (26). Overall, these results 
reflect the fact that while inter-species differences are inevitable and 
some weaknesses may exist for use of the porcine model, merits for its 
ability to provide close predictions of human solubility are clear. 
Stemming from the combination of qualitative and quantitative as-
sessments of porcine fluids post SEDDS ingestion, solubility at 1 h post 
SEDDS ingestion appeared highest for both gastric and USI fluids. 
Therefore, it appears that in order to accurately represent the maximum 
solubility estimate for dose number solubility classification, as outlined 
in the Developability Classification System (DCS), use of this 1 h media 
would provide the best solubility approximation when a SEDDS 
approach is considered. Accordingly, using knowledge obtained from 
the porcine fluid assessments in this study, in vitro testing was conducted 
to assess if this solubility estimate could be closely replicated in vitro 
using supplemented biorelevant media under optimal screening condi-
tions. While use of in vitro models provide welcomed resources to predict 
in vivo formulation performance, they remain only as accurate as the 
precision of the experimental parameters upon which they are based. 
Even though appropriate simulation of in vivo relevant fluid volumes has 
been suggested to be critical for correct implementation of bio- 
predictive tools (35), typically, testing parameters utilised, including 
dilutions, are taken from previous research and repeated, which may not 
represent an accurate bio-simulation of the conditions being replicated. 
Resultantly, it was hypothesised that a refined biorelevant medium 
reflecting the highest solubility observed from the microscopic and 
quantitative assessments in this study, could provide a more predictive 
and physiologically relevant estimation of how the GIT responds to 
SEDDS ingestion. In order to investigate which in vitro dispersion con-
ditions provided the closest estimate of the 1 h ex vivo result, five 
different ratios of SEDDS dispersed (1:50, 1:100, 1:200, 1:500 and 
1:1000) in three different biorelevant media were tested. These disper-
sions were selected as being reflective of the current physiological vol-
umes suggested for the human small intestine, which vary from 
approximately 50-1100 mL (36, 37), while approximation is compli-
cated through complementary presence of absorption. While the testing 
dilutions also approximated the 250 mL BCS solubilisation parameter 
(38) and 500 mL Developability Classification System (DCS) dose 
number solubilisation parameter (39), they also considered dilutions 
typically used for in vitro dynamic dispersion testing using dissolution 
testing apparatus (USP 2) (10, 32). As such, this also aimed to provide 
justification for traditional dispersion practises used in current in vitro 
tools to reflect the maximum solubilisation effect of 1 g of SEDDS 
administered in an in vivo study, a typical desired dose for humans. 
Accordingly, this work succeeded in verifying that a 1:200 dispersion 
of SEDDS in biorelevant media provides the closest simulation of 
maximum ex vivo solubility after 1 h upon administration of 1 g of 
SEDDS. SEDDS dispersed 1:200 in all three media (FaSSGF, FaSSIF and 
FaSSIFp) displayed no statistically significant differences from the ex 
vivo 1 h SEDDS solubility value in gastric and USI porcine fluids (Fig. 6). 
Suggesting that biorelevant media containing 1:200 dispersed SEDDS 
should be used to accurately reflect likely maximum solubility in vivo 
after 1 h when 1 g of SEDDS is administered. Furthermore, as no sta-
tistically significant differences were found between solubility in the 
(1:200) FaSSGF, FaSSIF, FaSSIFp, or the ex vivo 1 h SEDDS gastric and 
USI samples, the earlier hypothesis, from the microscopy and solubility 
assessments, regarding the importance of the SEDDS droplets for sol-
ubilisation was reinforced. As these similar solubility values suggest that 
Fig. 6. Maximum fenofibrate ex vivo solubility in Gastric and USI luminal fluid 
1 h after SEDDS administration compared to FaSSGF, FaSSIF and FaSSIFp media 
supplemented with 1:50, 1:100, 1:200, 1:500, 1:1000 dispersions of SEDDS. A 
one-way ANOVA and Tukey post-test revealed no significant difference be-
tween solubility in the porcine fluids versus the three biorelevant media with a 
1:200 dilution. A predicted solubility upon SEDDS dispersion in FaSSIF from 
MLR also displayed no significant difference from the ex vivo USI result. * 
represents a significant difference (p < 0.05) of mean solubility compared the 
ex vivo solubility measurement in each graph i.e. 1 h Gastric Ex Vivo or 1 h USI 
Ex Vivo. 
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the SEDDS excipients are primarily driving fenofibrate solubility in the 
SEDDS dispersions in contrast to any altered concentrations of bile salts 
and phospholipids or products of digestion in the respective medias. 
Additionally, accuracy of a previously published in silico tool for pre-
dicting solubility gain and resultantly dose number and DCS classifica-
tion upon SEDDS dispersion in biorelevant media was verified when the 
predicted value (297 µg/mL) was similar to the ex vivo (1 h USI) and in 
vitro (1:200) solubility estimates (Fig. 6). Therefore, accurate prediction 
of the in vivo and in vitro measurements through this in silico modelling 
reinforces its applicability to reliably predict dose numbers with SEDDS. 
Overall, an improved in vitro screening tool using appropriately 
concentrated SEDDS dispersions accurately predicted maximum in vivo 
drug solubility, demonstrating the significance of in vitro tool validation. 
5. Conclusion 
Overall, implications of this work for wider research are numerous. 
The ability of microscopic and solubility analysis of porcine fluids to 
refine in vitro predictions with SEDDS was realised upon demonstration 
that solubility at 1 h post SEDDS administration was closely matched by 
a 1:200 dispersion of SEDDS in various biorelevant media. Resultantly, 
this study demonstrates that tailoring of formulation screening with 
refined bio-relevant inputs is of the utmost importance. While there will 
always remain a need for certain in vivo studies, characterisation of these 
systems can lessen dependence and aid progression to a more confir-
matory, rather than exploratory role, via improvements in the predictive 
power of in vitro tools. Furthermore, this study represents the first 
characterisation of GI colloidal phases in pigs using advanced micro-
scopic techniques, forming the basis for a better understanding of the 
landrace pig as a model for evaluating drug bioavailability from SEDDS, 
while providing increasing evidence for its close representation of 
human solubilisation capacity. Overall, through integration of qualita-
tive and quantitative ex vivo porcine GI fluid characterisations and sol-
ubility estimates with in vitro tools, this work has demonstrated that 
refined predictions of in vivo drug solubility are achievable. 
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